Anaplastic lymphoma kinase fusion protein expression is associated with a favorable prognosis in resected invasive mucinous lung adenocarcinoma: A retrospective study from two Chinese tertiary hospitals

Background: Invasive mucinous adenocarcinoma (IMA) is a distinct variant of lung adenocarcinoma, which typically has a worse survival. However, its pathogenesis is potentially associated with a high degree of molecular heterogeneity, which might determine its different prognosis. Methods: We retrospectively analyzed 2207 consecutive lung adenocarcinoma patients who underwent radical resection at Qilu Hospital of Shandong University and Shandong Provincial Hospital from 2013 to 2019. Anaplastic lymphoma kinase (ALK) fusion protein expression was routinely detected by immunohistochemistry. The clinicopathological characteristics and treatment outcomes of IMA patients were retrieved, and compared between ALK-positive and ALK-negative IMA patients as well as between pure IMA and mixed IMA patients. The last follow-up was on December 31, 2020, and the median follow-up was 42 months. Results: A total of 98 patients (4.4%) were diagnosed with IMA. ALK protein expression was positive in 24.5% of IMAs, which was significantly higher than that of non-IMA lung adenocarcinomas (4.7%, P < 0.001). ALK-positive and ALK-negative IMA, as well as pure IMA and mixed IMA, showed similar distribution in terms of patients' age, gender and smoking history, stage, and primary tumor location, except for a higher rate of lymph node metastasis in mixed IMA (22.0% vs. 46.2%, P = 0.012). Five cases (20.8%) of ALK-positive IMAs and 28 cases (40.6%) of ALK-negative IMAs experienced recurrence. Multivariable-adjusted Cox regression analysis demonstrated that ALK expression was a favorable prognostic factor for both disease-free survival (hazard ratio [HR]: 0.354; 95% confidence interval [CI]: 0.131–0.960; P = 0.041) and overall survival (HR: 0.138; 95% CI: 0.029–0.658; P = 0.013) in resected IMA. No difference in disease-free survival (HR: 0.524; 95% CI: 0.237–1.157; P = 0.110) and OS (HR: 0.553; 95% CI: 0.199–1.537; P = 0.256) was observed between pure IMA and mixed IMA. Conclusion: Invasive mucinous lung adenocarcinoma showed higher ALK protein expression, which was a favorable prognostic factor for survival in early resected patients.

[1]  Edward S. Kim,et al.  Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer , 2021, Molecular Cancer Therapeutics.

[2]  Wei Chen,et al.  Clinical Relevance of PD-L1 Expression and CD8+ T Cells’ Infiltration in Patients With Lung Invasive Mucinous Adenocarcinoma , 2021, Frontiers in Oncology.

[3]  Xiancong Huang,et al.  Genomic Profiling and Prognostic Value Analysis of Genetic Alterations in Chinese Resected Lung Cancer With Invasive Mucinous Adenocarcinoma , 2021, Frontiers in Oncology.

[4]  Y. Yatabe,et al.  Comparison of Surgical Outcomes Between Invasive Mucinous and Non-Mucinous Lung Adenocarcinoma. , 2020, The Annals of thoracic surgery.

[5]  S. Viswanath,et al.  A clinico-epidemiological, pathological, and molecular study of lung cancer in Northwestern India , 2020, Journal of cancer research and therapeutics.

[6]  M. Ladanyi,et al.  Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Y. Ishikawa,et al.  Mucinous lung adenocarcinoma, particularly referring to EGFR‐mutated mucinous adenocarcinoma , 2019, Pathology international.

[8]  Shun Lu,et al.  Prognostic significance of anaplastic lymphoma kinase rearrangement in patients with completely resected lung adenocarcinoma. , 2019, Journal of thoracic disease.

[9]  Yan-Ze Jin,et al.  Histology and oncogenic driver alterations of lung adenocarcinoma in Chinese. , 2019, American journal of cancer research.

[10]  Yu-An Dong,et al.  Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. , 2019, The oncologist.

[11]  J Zhang,et al.  Clinicopathological Features of ALK Expression in 9889 Cases of Non-small-Cell Lung Cancer and Genomic Rearrangements Identified by Capture-Based Next-Generation Sequencing: A Chinese Retrospective Analysis , 2019, Molecular Diagnosis & Therapy.

[12]  Z. Zhan,et al.  Comparison of Clinicopathological Features and Prognosis between ALK Rearrangements and EGFR Mutations in Surgically Resected Early-stage Lung Adenocarcinoma , 2019, Journal of Cancer.

[13]  David R. Jones,et al.  Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. , 2018, Lung cancer.

[14]  Yuki Matsumura,et al.  Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non–Small Cell Lung Cancer: Brief Report , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  Jesse S. Voss,et al.  Pulmonary invasive mucinous adenocarcinoma and mixed invasive mucinous/nonmucinous adenocarcinoma-a clinicopathological and molecular genetic study with survival analysis. , 2018, Human pathology.

[16]  J. Wampfler,et al.  Growth pattern-based grading of pulmonary adenocarcinoma-Analysis of 534 cases with comparison between observers and survival analysis. , 2017, Lung cancer.

[17]  M. Landriscina,et al.  ALK rearrangement in specific subtypes of lung adenocarcinoma: immunophenotypic and morphological features , 2017, Medical Oncology.

[18]  S. Dacic Pros: the present classification of mucinous adenocarcinomas of the lung. , 2007, Translational lung cancer research.

[19]  J. Pyo,et al.  ALK Immunohistochemistry for ALK Gene Rearrangement Screening in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis , 2016, The International journal of biological markers.

[20]  L. Zhao,et al.  [Expression of ALK protein in 7 371 pulmonary adenocarcinoma samples, with analysis of clinicopathologic features]. , 2016, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[21]  J. Choi,et al.  Prognosis in Resected Invasive Mucinous Adenocarcinomas of the Lung: Related Factors and Comparison with Resected Nonmucinous Adenocarcinomas , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  Shun Lu,et al.  Frequencies of ALK rearrangements in lung adenocarcinoma subtypes: a study of 2299 Chinese cases , 2016, SpringerPlus.

[23]  L. Macconaill,et al.  KRAS and NKX2‐1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  Z. Madjd,et al.  Evaluation of anaplastic lymphoma kinase expression in nonsmall cell lung cancer;a tissue microarray analysis. , 2016, Journal of Cancer Research and Therapeutics.

[25]  J. Ying,et al.  Detection of ALK translocation in non-small cell lung carcinoma (NSCLC) and its clinicopathological significance using the Ventana immunohistochemical staining method: a single-center large-scale investigation of 1, 504 Chinese Han patients , 2016, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[26]  Yang Zhang,et al.  Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations , 2016, Journal of Cancer Research and Clinical Oncology.

[27]  Maristela L Onozato,et al.  Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  Lixin Wei,et al.  The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma , 2015, Tumor Biology.

[29]  C. Dooms,et al.  Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Prasad S Adusumilli,et al.  Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma: Invasive Mucinous Pattern and Extracellular Mucin Are Associated With KRAS Mutation , 2014, The American journal of surgical pathology.

[31]  Y. Nakanishi,et al.  Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  W. Travis,et al.  New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Yang Zhang,et al.  Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. , 2013, Lung cancer.

[34]  R. Marks,et al.  Worse Disease-Free Survival in Never-Smokers with ALK+ Lung Adenocarcinoma , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.